← All trials
NCT00159081
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2000
- Primary completion
- Jun 1, 2005
- Completion date
- Jun 1, 2005
- First posted
- —
- Last posted
- —
- Enrollment
- 159
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of DuesseldorfLead sponsor
- University of DuesseldorfStudy chair
- University of BonnCollaborator
- University of CologneCollaborator
- RWTH Aachen UniversityCollaborator
- University of TuebingenCollaborator
- Friedrich Schiller UniversityCollaborator
- University of GoettingenCollaborator
- German Federal Ministry of Education and ResearchCollaborator
- German Research Network On SchizophreniaCollaborator
- University of MannheimCollaborator
- Johnson and JohnsonCollaborator
- Martin Luther UniversityCollaborator
- Julius-Maximilians UniversityCollaborator
- Johannes Gutenburg UniversityCollaborator
- University of Duisburg-EssenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.